No cardiac safety concerns reported with a pharmaceutically manufactured cannabidiol formulation
Reports and Proceedings
Updates every hour. Last Updated: 30-Jul-2025 10:11 ET (30-Jul-2025 14:11 GMT/UTC)
Cannabidiol – which lacks the psychotropic effects of cannabis – has been shown to have beneficial effects on inflammation in myocarditis and pericarditis models.
A prospective placebo-controlled trial was conducted with an oral pharmaceutically manufactured (GMP) cannabidiol formulation in patients at high risk of cardiovascular events who were hospitalised for non-critical COVID-19 infection.
GMP-cannabidiol formulation was well tolerated with a similar low rate of overall and cardiac side effects as placebo, supporting its study in further trials.
A new study published in Science Advances reveals that a single gene plays a big role in how the liver stores energy, a process that's critical for overall health and for managing diseases like type 2 diabetes. Led by Penn Nursing’s Kate Townsend Creasy, PhD, Assistant Professor of Nutrition Science in the Department of Biobehavioral Health Sciences, the research focuses on the PPP1R3B gene. This gene tells the liver how to handle energy: store it as glycogen (a form of sugar) or triglycerides (a type of fat).